Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy

References

• Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:123–8.
   PubMed Web of Science ®Google Scholar
• Ohman L, Dahlen R, Isaksson S, Sjoling A, Wick MJ, Sjovall H, et al. Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease. Inflamm Bowel Dis 2013;19:2433–9.
   Google Scholar
• Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol 2012;47:538–47.
   PubMed Web of Science ®Google Scholar
• Olsen T, Goll R, Cui G, Husebekk A, Vonen B, Birketvedt GS, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol 2007;42:1312–20.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Peralvarez ML, Garcia-Sanchez V, Villar-Pastor CM, Gonzalez R, Iglesias-Flores E, Muntane J, et al. Role of serum cytokine profile in ulcerative colitis assessment. Inflamm Bowel Dis 2012;18:1864–71.
   Google Scholar
• Holmen N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjovall H, et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 2006;12:447–56.
   PubMed Web of Science ®Google Scholar
• Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008;126:121–36.
   PubMed Web of Science ®Google Scholar
• Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009;44:727–35.
   PubMed Web of Science ®Google Scholar
• Hassan C, Ierardi E, Burattini O, De Francesco V, Zullo A, Stoppino G, et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007;39:811–17.
   PubMedGoogle Scholar
• Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009;58:1612–19.
   PubMed Web of Science ®Google Scholar
• Moriconi F, Raddatz D, Ho NA, Yeruva S, Dudas J, Ramadori G. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. Transl Res 2007;150:223–32.
   PubMed Web of Science ®Google Scholar
• Dahlen R, Strid H, Lundgren A, Isaksson S, Raghavan S, Magnusson MK, et al. Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis. Scand J Immunol 2013;78:275–84.
   PubMed Web of Science ®Google Scholar
• Magnusson MK, Dahlen R, Strid H, Isaksson S, Simren M, Lasson A, et al. CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis. United European Gastroenterol J 2013;1:467–76.
   PubMed Web of Science ®Google Scholar
• Olsen T, Goll R, Cui G, Christiansen I, Florholmen J. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine 2009;46:222–7.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer SC, Stallmach A. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn’s disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis 2007;13:65–70.
   PubMed Web of Science ®Google Scholar
• Wolf D, D’Haens G, Sandborn WJ, Colombel JF, Van Assche G, Robinson AM, et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther 2014;40:486–97.
   PubMed Web of Science ®Google Scholar
• Martinez-Borra J, Lopez-Larrea C, Gonzalez S, Fuentes D, Dieguez A, Deschamps EM, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn’s disease. Am J Gastroenterol 2002;97:2350–6.
   PubMed Web of Science ®Google Scholar
• Ogawa K, Matsumoto T, Esaki M, Torisu T, Iida M. Profiles of circulating cytokines in patients with Crohn’s disease under maintenance therapy with infliximab. J Crohns Colitis 2012;6:529–35.
   PubMed Web of Science ®Google Scholar
• Katz LH, Kopylov U, Fudim E, Yavzori M, Picard O, Ungar B, et al. Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn’s disease treated with anti-TNF antibodies. Clin Res Hepatol Gastroenterol 2014;38:491–8.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn’s disease: a prospective pilot study. Inflamm Bowel Dis 2009;15:1460–6.
   PubMed Web of Science ®Google Scholar
• Liu C, Xia X, Wu W, Wu R, Tang M, Chen T, et al. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn’s disease. Clin Exp Immunol 2013;173:102–11.
   PubMed Web of Science ®Google Scholar
• Li Z, Arijs I, De Hertogh G, Vermeire S, Noman M, Bullens D, et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010;16:1299–310.
   PubMed Web of Science ®Google Scholar
• Allen JE, Sutherland TE. Host protective roles of type 2 immunity: parasite killing and tissue repair, flip sides of the same coin. Semin Immunol 2014;26:329–40.
   PubMed Web of Science ®Google Scholar